Somatic cell nuclear transfer and transcription-factor-based reprogramming revert adult cells to an embryonic state, and yield pluripotent stem cells that can generate all tissues. Through different mechanisms and kinetics, these two reprogramming methods reset genomic methylation, an epigenetic modification of DNA that influences gene expression, leading us to hypothesize that the resulting pluripotent stem cells might have different properties. Here we observe that low-passage induced pluripotent stem cells (iPSCs) derived by factor-based reprogramming of adult murine tissues harbour residual DNA methylation signatures characteristic of their somatic tissue of origin, which favours their differentiation along lineages related to the donor cell, while restricting alternative cell fates. Such an 'epigenetic memory' of the donor tissue could be reset by differentiation and serial reprogramming, or by treatment of iPSCs with chromatin-modifying drugs. In contrast, the differentiation and methylation of nuclear-transfer-derived pluripotent stem cells were more similar to classical embryonic stem cells than were iPSCs. Our data indicate that nuclear transfer more readily establishes the ground state of pluripotency than factor-based reprogramming, which can leave an epigenetic memory of the tissue of origin that may influence efforts at directed differentiation for applications in disease modelling or treatment.
Somatic cell nuclear transfer and transcription-factor-based reprogramming revert adult cells to an embryonic state, and yield pluripotent stem cells that can generate all tissues. Through different mechanisms and kinetics, these two reprogramming methods reset genomic methylation, an epigenetic modification of DNA that influences gene expression, leading us to hypothesize that the resulting pluripotent stem cells might have different properties. Here we observe that low-passage induced pluripotent stem cells (iPSCs) derived by factor-based reprogramming of adult murine tissues harbour residual DNA methylation signatures characteristic of their somatic tissue of origin, which favours their differentiation along lineages related to the donor cell, while restricting alternative cell fates. Such an 'epigenetic memory' of the donor tissue could be reset by differentiation and serial reprogramming, or by treatment of iPSCs with chromatin-modifying drugs. In contrast, the differentiation and methylation of nuclear-transfer-derived pluripotent stem cells were more similar to classical embryonic stem cells than were iPSCs. Our data indicate that nuclear transfer more readily establishes the ground state of pluripotency than factor-based reprogramming, which can leave an epigenetic memory of the tissue of origin that may influence efforts at directed differentiation for applications in disease modelling or treatment.
Direct reprogramming of somatic cells with the transcription factors
Oct4 (also called Pou5f1), Sox2, Klf4 and Myc 1 yields iPSCs with marked similarity to embryonic stem cells from fertilized embryos (fESCs). Like fESCs, iPSCs form teratomas, differentiated tumours with tissues from all three embryonic germ layers, and when injected into murine blastocysts contribute to all tissues, including the germ line. iPSCs from mouse embryo fibroblasts generate 'all-iPSC mice' after injection into tetraploid blastocysts 2 , thereby satisfying the most stringent criterion of pluripotency 3 . Embryonic tissues are the most efficiently reprogrammed, producing iPSCs that are nearly identical to fESCs. In contrast, reprogramming from accessible adult tissues, most applicable for modelling diseases and generating therapeutic cells, is inefficient and limited by barriers related to the differentiation state and age of the donor's cells [4] [5] [6] . Aged cells have higher levels of Ink4/Arf, which limits the efficiency and fidelity of reprogramming 5 . Moreover, terminally differentiated blood cells reprogram less efficiently than blood progenitors 6 . As with cloning by nuclear transfer in frogs and mice, the efficiency and yield of reprogrammed genomes declines with increasing age and differentiation status of the donor cell 7 , and varies with the methylation state of the donor nucleus 8 .
Different tissues show variable susceptibility to reprogramming. Keratinocytes reprogram more readily than fibroblasts 9 , and iPSCs from stomach or liver cells harbour fewer integrated proviruses than fibroblasts, indicating that they require lower levels of the reprogramming factors to achieve pluripotency 10 . When differentiated into neurospheres, iPSCs from adult tail-tip fibroblasts retain more teratomaforming cells than iPSCs from embryonic fibroblasts, again indicating heterogeneity based on the tissue of origin 11 . Moreover, cells can exist in intermediate states of reprogramming that interconvert with continuous passage or treatment with chromatin-modifying agents 12, 13 . Although generic iPSCs are highly similar to fESCs, in practice iPSCs generated from various tissues may harbour significant differences, both functional and molecular.
Transcription factor reprogramming differs markedly from nuclear transfer, particularly with regard to DNA demethylation, which commences immediately upon transfer of a somatic nucleus into ooplasm 14 , but occurs over days to weeks during the derivation of iPSCs 13 . Because demethylation is a slow and inefficient process in factor-based reprogramming, we postulated that residual methylation might leave iPSCs with an 'epigenetic memory', and that methylation might be more effectively reset by nuclear transfer. Here we compare the differentiation potential and genomic methylation of multiple classes of pluripotent stem cells-iPSCs, nuclear transfer ESCs (ntESCs) and fESCs-and find evidence that iPSCs indeed retain a methylation signature of their tissue of origin.
Initially we sought to compare the in vivo engraftment potential of haematopoietic stem cells derived from fESCs, ntESCs and iPSCs in a therapeutic mouse model of thalassaemia. However, even in vitro we observed markedly different blood-forming potential; thus, we focused here instead on understanding this phenomenon. Our initial set of pluripotent stem cells was derived from the hybrid C57BL/6 3 CBA (B6/CBAF1) strain carrying a deletion in the b-globin locus 15 , which for this study is otherwise immaterial (Fig. 1a ). We isolated fESCs from naturally fertilized embryos and derived ntESCs from nuclei of dermal fibroblasts 8 . We infected bone marrow progenitor cells (Kit 1 , Lin 2 , CD45 1 ) or dermal fibroblasts from aged mice with retroviral vectors carrying Oct4, Sox2, Klf4 and Myc, and selected blood-derived and fibroblast-derived iPSC colonies (B-iPSCs, F-iPSCs). Haematopoietic progenitors and fibroblasts from aged mice yielded a comparable frequency of reprogrammed colonies (0.02%), which consistent with previous reports 5 , was lower than the yield from fibroblasts of a juvenile mouse (0.1%). We characterized the fESC, ntESC and iPSC lines for expression of Oct4 and Nanog by immunohistochemistry, and demonstrated multilineage differentiation potential in teratomas (Fig. 1b, c and Supplementary Fig. 1 ). By criteria typically applied to human samples and appropriate for a therapeutic model 3 , all stem cell lines manifest pluripotency.
Differentiation of pluripotent stem cells
To test blood potential, we differentiated multiple pluripotent stem cell clones into embryoid bodies, dissociated cells, and assayed for haematopoietic colony forming cells 16 . All pluripotent cells generated comparable embryoid bodies but markedly different numbers of haematopoietic colonies. Consistently, blood-derived B-iPSCs yielded more haematopoietic colonies than F-iPSCs ( Fig. 2a ). Haematopoietic colony formation from ntESC and fESC lines was higher than the iPSC lines.
We then tested differentiation into osteoblasts, a mesenchymal lineage that can be derived from fibroblasts 17, 18 . By Alizarin red staining, a marker of osteogenic cells 19 , F-iPSCs produced more sharply defined osteogenic colonies ( Fig. 2b) , deposited more elemental calcium ( Fig. 2c ), and showed higher expression of three osteoblastassociated genes ( Fig. 2d) show enhanced osteogenic potential, reflecting a propensity to differentiate towards a mesenchymal lineage. In contrast, ntESCs behaved comparably to fESCs in haematopoietic and osteogenic assays.
DNA methylation of pluripotent stem cells
We hypothesized that the different pluripotent cells might harbour different patterns of genomic DNA methylation; thus, we performed comprehensive high-throughput array-based relative methylation (CHARM) analysis, which interrogates ,4.6 million CpG sites, including almost all CpG islands and nearby sequences, termed shores 20,21 , but does not assess non-CpG methylation. We determined the number of differentially methylated regions (DMRs) between pairwise comparisons, using a threshold area cutoff of 2, corresponding to a 5% false discovery rate (FDR 22 ; Supplementary Table 1a ). By this analysis, ntESCs were most similar to fESCs (only 229 DMRs), whereas F-iPSCs differed most extensively (5, 304 DMRs) . Relative to fESCs, hypermethylated DMRs predominated for F-iPSCs (3,349 5 63%) and B-iPSCs (516 5 74%). Highlighting their functional differences, 5,202 DMRs were identified between B-iPSCs and F-iPSCs. We confirmed the results of CHARM analysis by bisulphite pyrosequencing of multiple loci ( Supplementary Fig. 2 ). Unsupervised hierarchical clustering of DMRs between B-iPSCs and F-iPSCs easily distinguished iPSCs from ntESCs and fESCs, which cluster together ( Fig. 3a) . B-iPSCs cluster nearer to ntESCs and fESCs than do F-iPSCs, which represent a markedly separate cluster. These data indicate that the methylation patterns of ntESCs are more like fESCs than are either B-iPSCs or F-iPSCs.
Several lines of evidence support a mechanistic link between differential methylation and haematopoietic propensity of iPSC lines. First, literature survey of genes for the top 24 DMRs that distinguish B-iPSCs and F-iPSCs links 11 to haematopoiesis and 3 to osteogenesis (Supplementary Table 2 ). Of the 11 haematopoietic loci, 10 are hypermethylated in F-iPSCs relative to B-iPSCs. Second, of 74 haematopoietic transcription factors, 20 are in or near DMRs that are hypermethylated in F-iPSCs versus B-iPSCs, twice that predicted by chance (P 5 0.0034; Fig. 3b left panel, Supplementary Fig. 3a and Supplementary Table 3 ). Similarly, of 764 fibroblast-specific genes, 115 are hypermethylated in B-iPSCs, twice that predicted by chance (P 5 10 25 ; Fig. 3b right panel). Given the correlation between methylation and transcriptional silencing 23 , our data suggest that iPSCs harbour epigenetic marks antagonistic to cell lineages distinct from the donor cell type.
We asked whether DMRs that distinguish B-iPSCs from fESCs might allow us to identify their haematopoietic lineage of origin. In a separate CHARM experiment, we examined genome-wide methylation in highly purified multipotent and lineage-specific haematopoietic progenitors (H. Ji, I. L. Weissman and A. P. Feinberg, unpublished data). Comparing DMRs in B-iPSCs to those that define haematopoietic progenitors, we observed that B-iPSCs cluster alongside common myeloid progenitors (CMPs) and are distant from common lymphoid progenitors (CLPs; Supplementary Fig. 4a and Supplementary Table  4 ), which is notable given that B-iPSCs were derived from Kit 1 , lineage-negative myeloid marrow precursors. Next, we asked whether the tissue of origin (bone marrow versus fibroblast) could be identified by the methylation state of tissue-specific DMRs in F-iPSCs, B-iPSCs and Bl-iPSCs (a B-lymphocyte-derived iPSC line described below). Using DMRs that distinguish fibroblast and bone marrow, and examining methylation in iPSCs and somatic cells from two different genetic backgrounds (B6CBA and B6129), we found that F-iPSCs cluster alongside fibroblasts, and are distant from bone marrow (Supplementary Fig. 4b) . Similarly, the haematopoietic-derived B-iPSCs and Bl-iPSCs grouped with somatic cells from bone marrow. Thus, residual methylation indicates the tissue of origin of iPSCs, and for blood derivatives even their precise lineage, further supporting the phenomenon of epigenetic memory in iPSCs.
Reprogrammed state of iPSCs and ntESCs
We postulated that the differing methylation signatures of B-iPSCs, F-iPSCs and ntESCs reflect disparate reprogramming, and confirmed this by two independent computational analyses. First, we overlapped DMRs that distinguish B-iPSCs, F-iPSCs and ntESCs from fESCs with genes specifically expressed in undifferentiated murine fESCs 24 . By this analysis, ntESCs showed the fewest DMRs at loci corresponding to the most highly expressed fESC-specific genes, and B-iPSCs showed fewer DMRs at these loci than F-iPSCs (Supplementary Fig. 5a ). Second, we overlapped DMRs with the DNA binding locations for seven transcription factors that compose a core protein network of pluripotency 25 , and found the fewest DMRs at core transcription factor binding sites in ntESCs, and less overlap in B-iPSCs than in F-iPSCs (Supplementary Table 5 ). These analyses indicate that F-iPSCs harbour more residual methylation than B-iPSCs at loci directly linked to the gene expression and pluripotency networks of fESCs, whereas ntESCs show the least differential methylation and seem closest to fESCs at these critical loci.
Further analysis of Oct4 and Nanog indicates that although both are detected by immunohistochemistry in B-iPSCs and F-iPSCs ( Fig. 1b) , Oct4 mRNA is fully expressed from a demethylated promoter in both types of iPSC, whereas Nanog mRNA is sub-optimally expressed from a promoter that retains considerable methylation in F-iPSCs ( Supplementary Fig. 6 ). When assessed by blastocyst chimaerism, B-iPSCs contribute to all tissues, including the germ line, whereas F-iPSCs contribute only poorly ( Supplementary Fig. 7a ), although they can be found in SSEA1 1 germ cells of the gonadal ridge ( Supplementary Fig. 7b ). Thus, whereas both B-iPSCs and F-iPSCs generate robust multilineage teratomas, satisfying criteria for pluripotency typically applied to human cells 3 , broader functional assessments available in the mouse system confirm their differential degree of reprogramming. In this comparison of iPSCs derived from accessible tissues of aged adult mice, bone marrow yields stem cells with superior features of pluripotency, but neither iPSC is equivalent to ntESCs or fESCs. 
Stringently defined pluripotent stem cells
To determine whether blood-forming potential differs among cell lines that satisfy more stringent criteria for pluripotency, we analysed lines derived from a uniform genetic background (B6/129F1) that all express a Nanog-eGFP reporter gene 26 , and for which pluripotency was demonstrated by blastocyst chimaerism and transmission through the germ line ( Fig. 4a , upper schema; Supplementary Table 6 ). Moreover, these studies involve 'secondary' iPSC lines derived from neural progenitor cells (NP-iPSCs 27 ) and B-lymphocytes (Bl-iPSCs 28 ) of mice chimaerized with iPSCs carrying proviruses that express doxycycline-inducible reprogramming factors from identical proviral integration sites. NP-iPSCs and Bl-iPSCs were compared to ntESCs generated from neural progenitor cells (NP-ntESCs 8 ), blood progenitor cells (B-ntESCs 29 ) and fibroblasts (F-ntESCs 29, 30 ), as well as fESCs. All cell lines were differentiated into embryoid bodies and assayed for haematopoietic colony forming activity 16 . Across multiple clones, we observed higher blood-forming potential of iPSCs derived from B lymphocytes (Bl-iPSCs) than from neural progenitors (NP-iPSCs; Fig. 4b ).
In contrast, we observed that ntESCs, regardless of tissue origin (fibroblasts, neural progenitors, or T cells), and fESCs displayed an equivalently robust blood-forming potential (Fig. 4b ). In this independent set of iPSC lines, qualified as pluripotent by stringent criteria, we again observed consistent differences in blood formation, with blood derivatives showing more robust haematopoiesis in vitro than neural derivatives.
Resetting differentiation propensity
Finally, we asked whether we could rescue the poor blood-forming potential of NP-iPSCs by differentiation into haematopoietic lineages 16, 31 , followed by a tertiary round of reprogramming back to pluripotency by doxycycline induction of the endogenous reprogramming factors (Fig. 4a, lower schema) . As a control, we differentiated NP-iPSCs into neural stem cells 8 , followed by tertiary reprogramming to pluripotency. Resulting iPSC clones were selected for expression of the Nanog-eGFP reporter and shown to express Oct4 and Nanog by immunohistochemistry ( Supplementary Fig. 8 ) and to chimaerize murine blastocysts ( Supplementary Fig. 9 ). The tertiary blood-derived B-NP-iPSCs showed higher haematopoietic colony-forming potential than the tertiary neural-stem-cell-derived NSC-NP-iPSCs (Fig. 4b) , and generated larger haematopoietic colonies with more cells per colony ( Supplementary Fig. 10a, b) . These data indicate that the poor blood-forming potential of secondary NP-iPSCs can be enhanced by differentiation into haematopoietic progeny, followed by tertiary reprogramming. In contrast, tertiary reprogramming via neural intermediates yields iPSCs that retain poor haematopoietic potential.
The reduced blood potential of NP-iPSCs might be explained by residual epigenetic marks that restrict blood fates or a lack of epigenetic marks that enable blood formation. We sought to determine whether treatment of NP-iPSCs with pharmacological modulators of gene expression and DNA methylation might reactivate latent haematopoietic potential. We treated NP-iPSCs in vitro with trichostatin A (TSA), a potent inhibitor of histone deacetylase 32 , and 5-azacytidine (AZA), a methylation-resistant cytosine analogue 33 . After 18 days of drug treatment, the resulting cells displayed higher blood-forming activity (NP-iPSC-TSA-AZA; Fig. 4b ). For unclear reasons, tertiary reprogramming through blood intermediates or drug treatment of NP-iPSCs produced altered ratios of colony subtypes, perhaps indicating different efficiencies of lineage reprogramming.
Methylation in secondary and tertiary iPSCs
We used CHARM to examine the 'methylome' of the germ-linecompetent pluripotent stem cells, the tertiary reprogrammed B-NP-iPSCs and NSC-NP-iPSCs, and the drug-treated NP-iPSCs (Fig. 4a ). In pairwise comparisons ( Supplementary Table 1b) , the NP-iPSCs showed only a small number of DMRs relative to fESCs (553), fewer than the numbers of DMRs distinguishing ntESCs from fESCs (679), indicating that selection using the Nanog-GFP reporter and derivation from young donor tissue yields more equivalently reprogrammed cells. Despite equivalent Nanog-GFP expression, B-lymphocytederived Bl-iPSCs harboured more DMRs (1, 485) relative to fESCs than did the NP-iPSCs. Cluster dendrogram analysis, using the most variable DMRs that distinguish Bl-iPSCs and NP-iPSCs, showed NP-iPSCs to be more similar to fESCs than are Bl-iPSCs, which represent a distinct cluster (Fig. 4c) . These data indicate that neural progenitors are more completely reprogrammed to an ESC-like state than blood donor cells. Cluster dendrogram analysis failed to distinguish among NP-iPSCs, ntESCs and fESCs, but assessment of the overlap of DMRs with loci for highly expressed ESC-specific genes 24 and core pluripotency transcription factor binding sites 25 indicated differences among these three pluripotent cell types, and reveal that ntESCs have the fewest DMRs affecting these critical loci ( Supplementary Fig. 5b ), again consistent with more complete reprogramming to pluripotency.
Relative to fESCs, hypermethylated DMRs predominated in NP-iPSCs and Bl-iPSCs (417 (75%) and 1,423 (96%), respectively; Supplementary Table 6 . b, Haematopoietic colony number per 100,000 embryoid body cells differentiated from the indicated cell lines. n 5 number of independent clones tested. Error bars indicate s.d., added for clones repeated three or more times. c, Cluster dendrogram using probes from DMRs that distinguish Bl-iPSCs and NP-iPSCs. Height (y axis) is Euclidean distance. Supplementary Table 1b ), confirming that even when pluripotency is documented by stringent criteria, iPSCs retain residual methylation. By analysis of overlapping DMRs, Bl-iPSCs cluster with progenitors of the lymphoid lineage (CLP) rather than the myeloid lineage (Supplementary Fig. 4a and Supplementary Table 4 ; H. Ji, I. L. Weissman and A. P. Feinberg, unpublished data). To illustrate this point, the Gcnt2 gene, which encodes the enzyme responsible for the blood group I antigen, and Gata2, a regulator of haematopoiesis and erythropoiesis, are both hypermethylated and transcriptionally silent in the lymphoid lineage. Bl-iPSCs showed hypermethylation at these loci relative to fESCs, whereas the myeloid-derived B-iPSCs did not (Supplementary Fig. 11 ). Thus, a methylation signature correctly identifies the blood lineage of origin of B-lymphocyte-derived iPSCs. Furthermore, we found that neural-related genes tended to be differentially methylated between Bl-iPSCs and NP-iPSCs ( Supplementary Fig. 3b ). Treatment of NP-iPSCs with TSA and AZA enhances blood-forming potential and increases hypomethylated DMRs (626; Supplementary  Table 1c ). We found significant overlap between these DMRs and genes enriched in mouse haematopoietic stem cells (MSigDG signature STEMCELL_HEMATOPOIETIC_UP; Supplementary Fig. 3c ), indicating that drug treatment erases inhibitory methylation signatures at haematopoietic loci.
We compared DMRs in iPSCs with high haematopoietic potential (B-NP-iPSCs and NP-iPSC-TSA-AZA cells) to those with low haematopoietic potential (NP-iPSCs and NSC-NP-iPSCs), and found that B-NP-iPSCs and NP-iPSC-TSA-AZA cells harboured higher genebody methylation of Wnt3 ( Supplementary Fig. 12 ), a gene which along with its homologue Wnt3a has a major role in blood development from fESCs 34 . The blood-deficient NP-iPSC and NSC-NP-iPSC lines lacked gene-body methylation. Although promoter methylation is repressive, gene-body methylation is seen in active genes 35 . When iPSCs were differentiated into embryoid bodies, the blood-prone NP-iPSC-TSA-AZA cells showed higher levels of Wnt3 and Wnt3a expression than the blood-deficient NP-iPSCs ( Supplementary Fig. 13a ). Interestingly, supplementation of the culture media with Wnt3a during embryoid body differentiation restored blood-forming potential in the blood-deficient NP-iPSC and NSC-NP-iPSC lines, but had little effect on the already robust haematopoietic potential of B-NP-iPSCs ( Supplementary Fig. 13b ). Albeit preliminary, these data correlate differential gene-body methylation and expression of the Wnt3 locus with enhanced blood-forming potential in iPSC lines.
Discussion
Here we demonstrate that iPSCs retain an epigenetic memory of their tissue of origin, which is not apparent when adult somatic cells are reprogrammed to pluripotent stem cells by nuclear transfer. Our data reveal several important principles that relate to the technical limitations inherent in the process of transcription-factor-based reprogramming, and which in practice influence the differentiation propensity of specific isolates of iPSCs.
First, our data confirm that tissue source influences the efficiency and fidelity of reprogramming [9] [10] [11] . From aged mice, blood cells were reprogrammed more closely to fESCs than dermal fibroblasts, which yielded only incompletely reprogrammed cells. Neural-progenitorderived iPSCs were most similar to fESCs, consistent with evidence that such cells can be reprogrammed with fewer transcription factors 36 . Whereas neural progenitors are not readily accessible, iPSCs can be generated by direct reprogramming of human blood 37 .
Second, analysis of DNA methylation reveals substantial differences between iPSCs and embryo-derived ESCs (ntESCs and fESCs). iPSCs derived from non-haematopoietic cells (neural progenitors and fibroblasts) retain residual methylation at loci required for haematopoietic fate, which manifests as reduced blood-forming potential in vitro. Residual methylation signatures link iPSCs to their tissue of origin, and even discriminate between the myeloid and lymphoid origins of blood-derived iPSCs. Previous studies reporting residual hypermethylation in iPSCs 22, 35 did not establish a link between DMRs at specific loci, tissue of origin, and altered differentiation potential. Although residual methylation is mostly repressive, we have shown for Wnt3 that residual gene-body methylation in blood-derived iPSCs is associated with enhanced blood potential. Interestingly, the poor blood potential of neural-progenitor-derived iPSCs, which lack this epigenetic mark and express lower levels of endogenous Wnt3, can be enhanced by supplementing differentiating cultures with exogenous Wnt3a cytokine, indicating that manipulating culture conditions can overcome epigenetic barriers.
Third, the differentiation propensity and methylation profile of iPSCs can be reset. When blood-deficient neural-progenitor-derived iPSCs (NP-iPSC) are differentiated into blood and then reprogrammed to pluripotency, their blood-forming potential is markedly increased. Alternatively, treatment of NP-iPSCs with chromatinmodifying compounds increases blood-forming potential and is associated with reduced methylation at haematopoietic loci. For some applications, epigenetic memory of the donor cell may be advantageous, as directed differentiation to specific tissue fates remains a challenge.
Fourth, nuclear-transfer-derived ESCs are more effectively reprogrammed than most iPSCs generated from adult somatic tissues. Like the immediate and rapid demethylation of the sperm pronucleus after fertilization, somatic nuclei are rapidly demethylated by nuclear transfer into ooplasm, prompting speculation that the egg harbours an active demethylase 14 . In contrast, demethylation is a late phenomenon in factor-based reprogramming, and probably occurs passively 13 . Studying how ooplasm erases methylation might identify biochemical functions that would enhance factor-based reprogramming. Failure to demethylate pluripotency genes is associated with intermediate or partial states of reprogramming 12, 27, 38 , and knock down of the maintenance methyltransferase DNMT1 or treatment with the demethylating agent 5-AZA can convert intermediate states to full pluripotency. Demethylation seems to be passage dependent 13 , and reprogramming efficiency correlates with the rate of cell division and the passage number 39 . In our experiments, we compared pluripotent stem cells of comparable low-passage number (Supplementary Table 6 ), but continued serial passage may homogenize the differentiation potential of pluripotent cell types. Additionally, optimized protocols for factorbased reprogramming may more effectively erase epigenetic memory.
The mRNA expression program of iPSCs and fESCs are markedly similar 40 . Minor differences in mRNA and microRNA expression have been reported, but serial passage 38 and removal of transgenes 41 reduce the differences. The Dlk1-Dio3 locus, the expression of which correlates with capacity to generate 'all-iPSC' mice 42 , is not differentially methylated and is expressed in at least some iPSC lines that manifest epigenetic memory (our own unpublished observations). Thus, even the most stringently defined iPSCs might retain epigenetic memory. Importantly, differences between iPSCs and fESCs may not manifest in the pluripotent state but only after differentiation, when the specific loci that retain residual epigenetic marks are expressed, influencing cell fates. Methylation is but one molecular feature of epigenetic memory in iPSCs. Faulty restoration of bivalent domains, which mark developmental loci with both active and repressive histone modifications 43 , and loss of pioneer factors, which in fESCs and iPSCs occupy enhancers of genes expressed only in differentiated cells 44 , represent two other potential mechanisms.
Although ideal, generic iPSCs may be functionally and molecularly indistinguishable from fESCs, we have shown in practice that even rigorously selected iPSCs can retain epigenetic marks characteristic of the donor cell that influence differentiation propensity. Epigenetic differences are unlikely to be essential features of iPSCs, but rather reflect stochastic variations associated with the technical challenges and passage dependence of achieving complete reprogramming. Given that we lack reporter genes for selecting human iPSCs, and cannot qualify their pluripotency by assaying embryo chimaerism, the behaviour of human cells will probably be influenced by epigenetic memory. Human ESCs can also manifest variable differentiation potential 45 . These data highlight our limited understanding of the epigenetic heterogeneity of pluripotent NATURE | Vol 467 | 16 September 2010 stem cells, and the need for improved methods to ensure reprogramming of somatic cells to a fully naive 'ground state' of pluripotency 46 . Note added in proof: K. Hochedlinger and colleagues have observed similar epigenetic memory in iPSCs from blood, fibroblast and muscle sources, and have documented extinction of the memory with continued passage in culture 47 .
METHODS SUMMARY
ES cells and iPSCs were cultured in ESC media containing 15% FBS, and 1,000 U ml 21 of LIF. For the reprogramming of somatic cells, retrovirus expressing Oct4, Sox2, Klf4 and Myc were introduced. For the somatic cells containing inducible reprogramming factors, the media was supplemented with 2 ng ml 21 of doxycycline. For DNA and RNA isolation, fESCs or iPSCs were trypsinized and re-plated onto new tissue culture dishes for 45 min to remove feeder cells, and nucleic acids were extracted from the non-adherent cell suspension. Genomic DNA methylation analysis and pyrosequencing were performed by previously published methods 20, 21 .
Full Methods and any associated references are available in the online version of the paper at www.nature.com/nature.
